Ensemble, Alexion in macrocycle discovery deal

Ensemble Therapeutics Corp. (Cambridge, Mass.) partnered with Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to use Ensemble's Ensemblin technology to discover macrocyclic compounds against undisclosed targets selected by Alexion for ultra-rare disorders. Ensemble will receive an undisclosed upfront payment and research support. The biotech also is eligible for undisclosed milestones. Alexion will have exclusive rights to develop and commercialize any resulting candidates. Alexion was up $2.89 to $111.58 on Thursday. ...